54591-64-9

Upstream product

• 54591-62-7 3-amino-4-methyl-5-nitrobenzoic acid 
• 72922-60-2 methyl 3-amino-4-methyl-5-nitrobenzoate 
• 49592-71-4 methyl 4-methyl-3,5-dinitrobenzoate 
• 1057652-89-7 Methyl 3-fluoro-4-methyl-5-nitro-benzoate 
• 16533-71-4 3,5-dinitro-p-toluic acid 

Downstream Products

• 125229-13-2 3-hydroxy-4-methyl-5-nitrobenzoic acid methyl ester 
• 33713-02-9 3-methoxy-4-methyl-5-nitrobenzoic acid methyl ester 
• 125229-15-4 methyl 3-amino-5-methoxymethoxy-4-methylbenzoate 
• 125229-14-3 methyl 3-methoxymethyloxy-4-methyl-5-nitrobenzene 
• 125229-16-5 3-Benzenesulfonylamino-5-methoxymethoxy-4-methyl-benzoic acid methyl ester 
• 125229-22-3 methyl (2S,3S)-3-[N-[1-benzenesulfonyl-4-methoxy-4-oxo-(2,3)-[N-(9-phenylfluoren-9-yl)aziridino]butyl]amino]-5-methoxymethoxy-4-methylbenzoate 
• 1315454-97-7 C₂₆H₃₅NO₅Si 
• 1315454-96-6 C₂₆H₃₃NO₆Si 
• 1315454-93-3 (+/-)-methyl 3-benzoyloxy-4-(2-hydroxybut-3-ynyl)-5-nitrobenzoate 
• 1315454-94-4 (+/-)-methyl 3-benzoyloxy-4-(2-hydroxypenta-3,4-dienyl)-5-nitrobenzoate 
• 1315454-95-5 (+/-)-methyl 3-amino-5-benzyloxy-4-(2-hydroxypenta-3,4-dienyl)benzoate 
• 187682-19-5 3-benzoyloxy-4-methyl-5-nitrobenzoic acid methyl ester 
• 704906-34-3 3-benzoyloxy-5-nitro-4-(2-oxoethyl)benzoic acid methyl ester 
• 1070887-37-4 C₁₁H₁₃NO₅ 

Relevant academic research and scientific papers

Orally active zwitterionic factor Xa inhibitors with long duration of action

We have optimized 2-aminomethylphenylamine derivative as a factor Xa inhibitor. Several polar functional groups were introduced in the central phenyl ring, and we focused on zwitter ionic compound showing continuous inhibitory activity in oral administrat

Development of a flexible strategy towards FR900482 and the mitomycins

FR900482 and the mitomycins are two intriguing classes of alkaloid natural products that have analogous biological mechanisms and obvious structural similarity. Both classes possess potent anticancer activity, a feature that has led to their investigation

PROLYL HYDROXYLASE INHIBITORS

The invention described herein relates to certain 2,4-dioxo-l,2,3,4-tetrahydro-7- quinazolinecarboxamide derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.